Skip to main content
. 2019 Jun;8(3):302–316. doi: 10.21037/tlcr.2019.04.12

Figure 2.

Figure 2

Progression-free survival to EGFR-TKI of NSCLC patients harboring common and common EGFR mutations. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer.